| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IBRX | Common Stock | Options Exercise | $0 | +114K | +0.39% | $0.00 | 29.6M | Feb 22, 2025 | Direct | F1 |
| transaction | IBRX | Common Stock | Tax liability | -$144K | -42.1K | -0.14% | $3.42 | 29.5M | Feb 22, 2025 | Direct | F2 |
| holding | IBRX | Common Stock | 246M | Feb 22, 2025 | See footnote | F3 | |||||
| holding | IBRX | Common Stock | 262M | Feb 22, 2025 | See footnote | F4 | |||||
| holding | IBRX | Common Stock | 8.38M | Feb 22, 2025 | See footnote | F5 | |||||
| holding | IBRX | Common Stock | 7.98M | Feb 22, 2025 | See footnte | F6 | |||||
| holding | IBRX | Common Stock | 5.62M | Feb 22, 2025 | See footnote | F7 | |||||
| holding | IBRX | Common Stock | 9.99M | Feb 22, 2025 | See footnote | F8 | |||||
| holding | IBRX | Common Stock | 47.6M | Feb 22, 2025 | See footnote | F9 | |||||
| holding | IBRX | Common Stock | 32.6M | Feb 22, 2025 | See footnote | F10 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IBRX | Restricted Stock Units | Options Exercise | $0 | -114K | -33.33% | $0.00 | 229K | Feb 22, 2025 | Common Stock | 114K | Direct | F1, F11 |
| Id | Content |
|---|---|
| F1 | Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock. |
| F2 | On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld. |
| F3 | Shares held by Nant Capital, LLC, an investment vehicle of the reporting person ("Nant Capital"). |
| F4 | Shares held by Cambridge Equities, LP ("Cambridge Equities"). MP 13 Ventures, LLC ("MP 13 Ventures") is the general partner of Cambridge Equities and may be deemed to have beneficial ownership of the shares held by Cambridge Equities. The reporting person is the sole member of MP 13 Ventures and has voting and dispositive power over the shares held by Cambridge Equities. |
| F5 | Shares held by NantBio, Inc. ("NantBio"). NantWorks, LLC ("NantWorks") is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the shares held by NantBio. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the shares held by NantBio. |
| F6 | Shares held by California Capital Equity, LLC ("CalCap"). The reporting person owns all of the equity interests of CalCap and has voting and dispositive power over the shares held by CalCap. |
| F7 | Shares held by the Chan Soon-Shiong Family Foundation, an exempt corporation organized under the laws of the State of Delaware (the "Foundation"). The Foundation has the sole power to vote and direct the disposition of all shares directly owned by the Foundation, except to the extent it may be deemed to share such power with the reporting person by virtue of the reporting person's control over the Foundation. The reporting person serves as Chairman of the Foundation. |
| F8 | Shares held by NantWorks, LLC ("NantWorks"). CalCap directly owns all of the equity interests of NantWorks and may be deemed to have beneficial ownership of the securities held by NantWorks. The reporting person directly owns all of the equity interests of CalCap and may be deemed to have voting and dispositive power over the securities held by NantWorks. |
| F9 | Shares held by NantMobile, LLC ("NantMobile"). NantWorks is the majority stockholder and an affiliate of NantMobile and may be deemed to have beneficial ownership of the securities held by NantMobile. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantMobile. |
| F10 | Shares held by NantCancerStemCell, LLC ("NCSC"). NantBio is the majority stockholder and an affiliate of NCSC and may be deemed to have beneficial ownership of the securities held by NCSC. NantWorks is the majority stockholder and an affiliate of NantBio and may be deemed to have beneficial ownership of the securities held by NantBio and its affiliates. The reporting person is the chief executive officer of NantWorks and indirectly beneficially owns all of the equity interests in NantWorks and may be deemed to have voting and dispositive power over the securities held by NantBio and its affiliates. |
| F11 | Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024. |
Founder, Executive Chairman, Global Chief Scientific and Medical Officer